Brown & Burk UK Limited's sourcing strategy exhibits a high degree of concentration, with a significant portion of their pharmaceutical imports originating from India. Between 2022 and 2026, the company imported finished pharmaceutical formulations valued at $16.5 million USD from India, encompassing 377 shipments and 1,186 unique formulations across six products and five therapeutic categories. The top five imported products include Gabapentin ($6.5 million, 0.8% share), Ramipril ($4.0 million, 4.4% share), Flucloxacillin ($3.4 million, 8.8% share), Clarithromycin ($1.6 million, 1.6% share), and Lisinopril ($852,000, 1.4% share). Notably, the top five products account for 99.1% of the total import value, indicating a highly concentrated product portfolio.
This sourcing concentration suggests a strategic choice by Brown & Burk UK Limited to focus on a select range of high-demand generic pharmaceuticals. The stability of their relationship with Indian suppliers, particularly MICRO LABS LIMITED, which accounts for 99.7% of the shipments, is crucial. The company's reliance on a single supplier for the majority of their imports may pose risks related to supply chain disruptions, pricing fluctuations, and geopolitical factors affecting trade relations.
